Policy Developments - The National Healthcare Security Administration announced that by November 1, 25 provinces, covering nearly 90% of the coordinated areas, will implement direct payment of maternity allowances to individuals [2] Drug and Medical Device Approvals - Jincheng Pharmaceutical's subsidiary received a drug registration certificate for a new antibacterial injection, which is effective against infections caused by sensitive bacteria [5] - Jiukang Bio announced the receipt of a medical device registration certificate for a test kit used to measure NT-proBNP levels in blood, enhancing the company's product offerings [6] - Xuantai Pharmaceutical received temporary approval from the FDA for its extended-release formulation of sitagliptin and metformin, which is used for managing type 2 diabetes [7] Financial Reports - Xiangsheng Medical reported a 41.95% year-on-year increase in net profit for Q3 2025, despite a 6.68% decline in revenue [9] - Weili Medical achieved a 16.09% increase in revenue for Q3 2025, with a net profit growth of 16.31% [10] Capital Market Activities - Riltide Medicines completed a seed round financing of several million RMB, aimed at advancing clinical research and developing an AI molecular design platform [12] - Yaojie Ankang announced plans to convert 44.97 million domestic shares into H-shares, representing approximately 11.33% of the total shares, pending regulatory approval [13] Industry Events - The National Medical Products Administration held a meeting to discuss the regulation of home medical devices, emphasizing the importance of quality management and regulatory compliance [15] - A custom brain-machine interface MRI platform was launched, marking a significant advancement in the clinical application of brain-machine interface technology [16] Shareholder Actions - Kangchen Pharmaceutical's major shareholder reduced their stake by 1.2%, decreasing their ownership from 46.65% to 45.45% [18]